SC amivantamab, in combination with LAZCLUZE, is recommended for adult patients with advanced NSCLC with epidermal growth ...

Helsinki-based Aplagon has raised EUR 7 million to advance its APAC therapeutic for thrombo-inflammatory diseases into phase ...

Cartesian Therapeutics has secured an agreement from the US Food and Drug Administration (FDA) under the Special Protocol ...

The US Food and Drug Administration (FDA) has approved Eisai and Biogen’s Supplemental Biologics License Application for once ...

Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for ...

Vedanta Biosciences has published additional results from its Phase 2 CONSORTIUM study for VE303, a potential first-in-class ...

Distributing reliable information about medicines is challenging for the pharma industry and the healthcare professionals ...

AstraZeneca has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for ...

This initiative, funded by the Innovative Health Initiative Joint Undertaking (IHI JU) with over EUR 38 million, aims to ...

The European Commission (EC) has approved the marketing authorisation for LAZCLUZE (lazertinib) in combination with RYBREVANT ...

Alliance Healthcare UK has announced that Paula Sutherland has been appointed to the position of Sales Director. Paula will ...

Yet only 5% have an approved therapy, and none offers a cure, leaving a significant unmet medical need. Due to the limited ...